Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001213900-13-004774
Filing Date
2013-08-22
Accepted
2013-08-22 16:56:48
Documents
1
Period of Report
2013-08-20

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT f4072513seth_actinium.html 4  
1 OWNERSHIP DOCUMENT f4072513seth_actinium.xml 4 5093
  Complete submission text file 0001213900-13-004774.txt   6520
Mailing Address 501 FIFTH AVENUE, 3RD FLOOR NEW YORK NY 10017
Business Address 501 FIFTH AVENUE, 3RD FLOOR NEW YORK NY 10017 212-300-2131
Actinium Pharmaceuticals, Inc. (Issuer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: NV | Fiscal Year End: 1231
SIC: 6770 Blank Checks

Mailing Address 300 E 93RD STREET, #20-B NEW YORK NY 10128
Business Address
SETH SANDESH (Reporting) CIK: 0001566175 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-52446 | Film No.: 131055682